Revenue: As of FY2026 Q1, the actual value is USD 67.86 K.EPS: As of FY2026 Q1, the actual value is USD -0.22.EBIT: As of FY2026 Q1, the actual value is USD -2.85 M.<h4>Segment Revenue</h4>Mangoceuticals, Inc. reported revenues of $67,864 for the three months ended March 31, 2026, which is a decrease from $109,306 for the same period in 2025, primarily due to focusing on in-house website development and testing a new TRT product in specific markets before a full launch.<h4>Operational Metrics</h4><ul><li>Cost of Revenues: The cost of revenues was $8,218 for the three months ended March 31, 2026, a decrease from $24,737 for the same period in 2025, attributed to fluctuations in third-party service provider usage, product promotions, and delivery costs.</li><li>Cost of Revenues - Related Party: Costs paid to Epiq Scripts, a related party pharmacy, increased to $30,645 for the three months ended March 31, 2026, from $22,505 in the prior year, due to increased use of third-party providers.</li><li>General and Administrative Expenses: These expenses decreased to $1,054,122 for the three months ended March 31, 2026, from $1,542,444 in 2025, mainly due to reduced consulting fees and insurance, partially offset by increased travel, legal, and accounting expenses.</li><li>Salaries and Benefits: Salaries and benefits slightly decreased to $346,860 for the three months ended March 31, 2026, from $349,783 in 2025, due to changes in personnel.</li><li>Advertising and Marketing Expenses: These expenses decreased to $94,073 for the three months ended March 31, 2026, from $281,732 in 2025, reflecting a reduction in advertising and marketing efforts while the company focused on its website re-launch and more targeted marketing.</li><li>Investor Relations Expenses: Investor relations expenses significantly decreased to $12,451 for the three months ended March 31, 2026, from $1,419,000 in 2025, due to a reduction in public awareness campaigns.</li><li>Stock-Based Compensation: Stock-based compensation increased to $1,647,821 for the three months ended March 31, 2026, from $1,045,479 in 2025, due to stock issuances for employees and consultants in lieu of cash.</li><li>Interest Expense: The company reported - $0 in interest expense for the three months ended March 31, 2026, compared to - $13,700 in 2025, due to the repayment of loans in prior periods.</li><li>Interest Expense - Amortization of Intangible Assets: This expense remained constant at $276,815 for both periods.</li><li>Net Loss: The net loss decreased to - $3,403,141 for the three months ended March 31, 2026, from - $4,839,489 in 2025, representing a reduction of $1,436,348 due to decreases in most operating expenses, except stock-based compensation.</li><li>Accumulated Deficit: As of March 31, 2026, the total accumulated deficit was - $44.1 million.</li><li>Working Capital Deficit: As of March 31, 2026, the company had a working capital deficit of - $0.5 million.</li></ul><h4>Cash Flow</h4><ul><li>Net Cash Used in Operating Activities: Net cash used in operating activities was - $1,311,343 for the three months ended March 31, 2026, primarily due to the - $3,403,141 net loss, partially offset by $1,090,114 in options vested for stock-based compensation and $589,107 from the issuance of common stock for services.</li><li>Net Cash Provided by Financing Activities: For the three months ended March 31, 2026, net cash provided by financing activities was - $0, compared to $2,285,000 in 2025, which included proceeds from the sale of common stock ($655,000), Series B Convertible Preferred Stock ($1,150,000), and warrants ($480,000).</li><li>Cash and Cash Equivalents: Cash on-hand decreased to $174,562 as of March 31, 2026, from $1,486,338 as of December 31, 2025, mainly due to funds used in operations with no additional fundraising during the period.</li></ul><h4>Unique Metrics and Strategic Summary</h4><ul><li>Current Products: Mangoceuticals, Inc. offers men’s wellness products including Mango (erectile dysfunction), Grow (hair loss), Mojo (hormone balance), Slim (weight loss), and Prime (testosterone replacement therapy).</li><li>Future Plans: The company has largely completed Phase II clinical trials and efficacy studies for its patented respiratory illness prevention technology and is determining next steps for commercialization. It also intends to commence operations for Dermytol, a brand of plant-based skin formulations, in the 3rd quarter of 2026 through a Master Distribution Agreement with Propre Energie, Inc.</li><li>Strategic Alternatives: In October 2024, the Board initiated a process to evaluate strategic alternatives, such as potential mergers, acquisitions, divestitures, and business combinations, to maximize shareholder value, though no specific transaction is assured.</li></ul><h4>Future Outlook and Strategy</h4>Mangoceuticals, Inc. anticipates needing additional funding within the next 12 months to sustain current operations and cover public company costs, potentially through equity or debt financing which may cause significant dilution. The company aims for organic growth and acquisitions in technology, health, and wellness, focusing on enhancing its platform and expanding men’s health and wellness product offerings. The company is not in compliance with Nasdaq’s minimum bid price requirement as of February 4, 2026, and faces potential delisting if it cannot regain compliance, especially given past reverse stock splits and cumulative ratio limitations. Furthermore, the company faces significant regulatory risk related to its reliance on a related-party compounding pharmacy under Section 503A of the FFD&amp;C Act, as increased FDA scrutiny could deem its operations closer to manufacturing, leading to more stringent requirements or enforcement actions.

Mangoceuticals | 10-Q: FY2026 Q1 Revenue: USD 67.86 K